ECG left ventricular hypertrophy as a risk predictor of sudden cardiac death.

Adult Aged Cohort Studies Death, Sudden, Cardiac / epidemiology Electrocardiography / methods Female Follow-Up Studies Health Surveys / methods Humans Hypertrophy, Left Ventricular / diagnosis Male Middle Aged Predictive Value of Tests Prospective Studies Risk Factors
Electrocardiography Epidemiology Left ventricular hypertrophy Sudden cardiac death

Journal

International journal of cardiology
ISSN: 1874-1754
Titre abrégé: Int J Cardiol
Pays: Netherlands
ID NLM: 8200291

Informations de publication

Date de publication:
01 Feb 2019
Historique:
received: 25 07 2018
revised: 20 09 2018
accepted: 25 09 2018
pubmed: 9 10 2018
medline: 28 8 2019
entrez: 9 10 2018
Statut: ppublish

Résumé

Electrocardiographic (ECG) left ventricular hypertrophy (LVH) is an established risk factor for cardiovascular events. However, limited data is available on the prognostic values of different ECG LVH criteria specifically to sudden cardiac death (SCD). Our goal was to assess relationships of different ECG LVH criteria to SCD. Three traditional and clinically useful (Sokolow-Lyon, Cornell, R After a mean follow-up of 12.5 ± 2.2 years, 134 SCDs had occurred. When used as continuous variables, all LVH criteria except for R Sokolow-Lyon, Cornell, and Peguero-Lo Presti ECG, but not R

Sections du résumé

BACKGROUND BACKGROUND
Electrocardiographic (ECG) left ventricular hypertrophy (LVH) is an established risk factor for cardiovascular events. However, limited data is available on the prognostic values of different ECG LVH criteria specifically to sudden cardiac death (SCD). Our goal was to assess relationships of different ECG LVH criteria to SCD.
METHODS METHODS
Three traditional and clinically useful (Sokolow-Lyon, Cornell, R
RESULTS RESULTS
After a mean follow-up of 12.5 ± 2.2 years, 134 SCDs had occurred. When used as continuous variables, all LVH criteria except for R
CONCLUSIONS CONCLUSIONS
Sokolow-Lyon, Cornell, and Peguero-Lo Presti ECG, but not R

Identifiants

DOI: 10.1016/j.ijcard.2018.09.104 PMID: 30293667
pubmed: 30293667
pii: S0167-5273(18)34606-0
doi: 10.1016/j.ijcard.2018.09.104
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

125-129

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2018 The Authors. Published by Elsevier B.V. All rights reserved.

Auteurs

Kimmo Porthan (K)

Division of Cardiology, Heart and Lung Center, Helsinki University Central Hospital, Helsinki, Finland. Electronic address: kimmo.porthan@fimnet.fi.

Tuomas Kenttä (T)

Research Unit of Internal Medicine, University Hospital of Oulu, University of Oulu, Finland.

Teemu J Niiranen (TJ)

THL-National Institute for Health and Welfare, Turku, Finland; THL-National Institute for Health and Welfare, Helsinki, Finland.

Markku S Nieminen (MS)

Division of Cardiology, Heart and Lung Center, Helsinki University Central Hospital, Helsinki, Finland.

Lasse Oikarinen (L)

Division of Cardiology, Heart and Lung Center, Helsinki University Central Hospital, Helsinki, Finland.

Matti Viitasalo (M)

Division of Cardiology, Heart and Lung Center, Helsinki University Central Hospital, Helsinki, Finland.

Jussi Hernesniemi (J)

Heart Center, Tampere University Hospital, Tampere, Finland; Faculty of Medicine and Life Sciences, University of Tampere, Finland.

Antti M Jula (AM)

THL-National Institute for Health and Welfare, Turku, Finland.

Veikko Salomaa (V)

THL-National Institute for Health and Welfare, Helsinki, Finland.

Heikki V Huikuri (HV)

Research Unit of Internal Medicine, University Hospital of Oulu, University of Oulu, Finland.

Christine M Albert (CM)

Division of Preventive Medicine, Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Jani T Tikkanen (JT)

Research Unit of Internal Medicine, University Hospital of Oulu, University of Oulu, Finland; Division of Preventive Medicine, Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › ECG left ventricular hypertrophy as a risk...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › ECG left ventricular hypertrophy as a risk...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › ECG left ventricular hypertrophy as a risk...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Mort › Mort subite › Mort subite cardiaque › ECG left ventricular hypertrophy as a risk...
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Électrodiagnostic › Électrocardiographie › ECG left ventricular hypertrophy as a risk...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études de suivi › ECG left ventricular hypertrophy as a risk...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Enquêtes et questionnaires › Enquêtes de santé › ECG left ventricular hypertrophy as a risk...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › ECG left ventricular hypertrophy as a risk...
questionsmedicales.fr › États, signes et symptômes pathologiques › États anatomopathologiques › Hypertrophie › Cardiomégalie › Hypertrophie ventriculaire gauche › ECG left ventricular hypertrophy as a risk...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › ECG left ventricular hypertrophy as a risk...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Méthodologie en recherche épidémiologique › Valeur prédictive des tests › ECG left ventricular hypertrophy as a risk...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études prospectives › ECG left ventricular hypertrophy as a risk...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Probabilité › Risque › Facteurs de risque › ECG left ventricular hypertrophy as a risk...